Press Release: Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis
Company announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity
MARIETTA, GA, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Shockwave Centers of America provides access to information about shockwave therapy providers near you through its online Find a Clinic directory. The resource brings together participating clinics across the United States and Puerto Rico, helping individuals identify providers that offer shockwave therapy in their local communities.
National recognition comes as Daré Bioscience advances a multi-product women’s health strategy across commercialization, clinical development and first-in-category innovation National recognition comes as Daré Bioscience advances a multi-product women’s health strategy across commercialization, clinical development and first-in-category innovation
Dubai, UAE, Aug. 17, 2026 (GLOBE NEWSWIRE) -- The Pepeto presale has passed $10 million, and this week's sharpest crypto news money flow explains why: anyone who read about Solana under $1 in 2020 and scrolled past gave up $293,000 per $1,000. That memory is doing the buying now, as the Solana price prediction turns…
